MD, Endocrinology Advanced Trainee, Department of Diabetes and Endocrinology, Blacktown-Mt Druitt Hospital, Sydney, NSW; Blacktown Clinical School, School of Medicine, Western Sydney University, Sydney, NSW.
MBBS, PhD, FRACP, Head of Endocrinology, Department of Diabetes and Endocrinology, Blacktown-Mt Druitt Hospital, Sydney, NSW; Blacktown Clinical School, School of Medicine, Western Sydney University, Sydney, NSW.
Aust J Gen Pract. 2021 Sep;50(9):628-632. doi: 10.31128/AJGP-03-21-5866.
Glycated haemoglobin, or HbA1c, is the main biomarker used to assess long-term glycaemic control in individuals with diabetes, and it correlates with the development of complications.
The aim of this article is to provide an overview of HbA1c to understand its role in the treatment of individuals living with diabetes. Topics discussed include recommended treatment targets, methods of measurement, causes of measurement inaccuracy and alternative means available to assess glycaemic control.
HbA1c should not be interpreted in isolation; the measurement accuracy and other parameters, including treatment goals and comorbidities, need to be considered.
糖化血红蛋白（HbA1c）是评估糖尿病患者长期血糖控制的主要生物标志物，与并发症的发生相关。
本文旨在概述 HbA1c，以了解其在糖尿病患者治疗中的作用。讨论的主题包括推荐的治疗目标、测量方法、测量不准确的原因以及评估血糖控制的替代方法。
HbA1c 不能孤立解读；需要考虑测量准确性和其他参数，包括治疗目标和合并症。
